This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy (CAR-T, Glofitamab or iR2 ).
Study Type
OBSERVATIONAL
Enrollment
150
Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School
Shanghai, China
RECRUITINGThe value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma
The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma
Time frame: Baseline and 2 weeks after treatment
Standardized uptake value (SUV)
SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
Time frame: Baseline and 2 weeks after treatment
Progress free suivival
Progress free suivival
Time frame: 3 years
Overall survival
Overall survival
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.